Global Corticosteroid Injections for Joint Pain Market Size By Type (Knee And Ankle, Hip Joint), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Corticosteroid Injections for Joint Pain Market was valued at USD 3.9 billion in 2023 and is projected to reach USD 6.4 billion by 2031, expanding at a CAGR of 6.7% during the forecast period (2023–2031). The market growth is driven by the increasing prevalence of arthritis and other joint-related disorders, rising geriatric population, and growing awareness about non-surgical pain management alternatives. Corticosteroid injections are widely used for immediate pain relief in conditions such as osteoarthritis, rheumatoid arthritis, bursitis, and tendonitis, offering targeted treatment with quick onset of action and minimal systemic effects.

Drivers:

1. Rising Prevalence of Joint Disorders:

A surge in cases of osteoarthritis, rheumatoid arthritis, and degenerative joint diseases globally is significantly driving the demand for corticosteroid injections as a primary pain management option.

2. Growing Geriatric Population:

Aging is a key risk factor for joint pain and inflammation. With the elderly population expanding worldwide, the need for corticosteroid-based interventions is expected to rise substantially.

3. Non-Surgical Treatment Preference:

Corticosteroid injections are increasingly preferred for their ability to provide localized pain relief without surgery, reducing downtime and hospitalization costs for patients.

Restraints:

1. Adverse Effects of Prolonged Use:

Repeated corticosteroid injections may lead to side effects such as joint infection, cartilage damage, and weakening of tendons, limiting long-term usage.

2. Short Duration of Effectiveness:

The temporary nature of relief provided by corticosteroids necessitates repeated injections, which may not be sustainable or advisable in chronic cases.

Opportunity:

1. Technological Advancements in Drug Delivery:

Innovations such as sustained-release corticosteroid formulations and ultrasound-guided delivery systems are enhancing efficacy and minimizing side effects, creating opportunities for product differentiation.

2. Expanding Healthcare Access in Emerging Markets:

Growing healthcare infrastructure and rising awareness in developing regions such as Asia-Pacific and Latin America are expected to unlock new growth opportunities for market players.

Market by System Type Insights:

By system type, Triamcinolone-based injections accounted for the largest market share in 2023 due to their long-lasting anti-inflammatory effects and established usage across orthopedic practices. However, Dexamethasone-based formulations are gaining momentum owing to their rapid action and minimal fluid retention side effects.

Market by End-use Insights:

The Hospital & Specialty Clinics segment led the market in 2023, contributing over 60% of the global revenue. The availability of advanced diagnostic tools and trained professionals in these facilities enhances the safety and precision of intra-articular injections. The Ambulatory Surgical Centers (ASCs) segment is anticipated to witness the highest growth rate, driven by shorter patient stays and cost-effective outpatient services.

Market by Regional Insights:

North America dominated the global market in 2023, supported by a high prevalence of arthritis, advanced healthcare infrastructure, and early adoption of novel drug delivery techniques. Meanwhile, Asia-Pacific is projected to experience the fastest growth during the forecast period, fueled by increasing healthcare expenditure, expanding patient base, and rising awareness about joint health.

Competitive Scenario:

Leading players in the global corticosteroid injections for joint pain market include Pfizer Inc., Mylan N.V., Sanofi S.A., Johnson & Johnson, Teva Pharmaceuticals, AbbVie Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., AstraZeneca plc, and Zydus Lifesciences Ltd. These companies are focusing on research and development of longer-acting corticosteroid formulations, strategic acquisitions, and expanding their geographical presence.

Scope of Work – Global Corticosteroid Injections for Joint Pain Market

Key Market Developments:

2023: Pfizer launched a next-generation triamcinolone injectable with enhanced tissue selectivity, extending the duration of joint pain relief.

2024: Teva Pharmaceuticals introduced a combination corticosteroid therapy for improved efficacy in chronic knee osteoarthritis patients.

2025: Johnson & Johnson announced clinical trials for a biodegradable corticosteroid implant designed for sustained intra-articular release.

FAQs:

1) What is the current market size of the Global Corticosteroid Injections for Joint Pain Market?

The market was valued at USD 3.9 billion in 2023.

2) What is the major growth driver of the Global Corticosteroid Injections for Joint Pain Market?

The primary growth driver is the rising prevalence of joint disorders and growing preference for non-surgical pain relief.

3) Which is the largest region during the forecast period in the Global Corticosteroid Injections for Joint Pain Market?

North America is expected to dominate the market throughout the forecast period.

4) Which segment accounted for the largest market share in the Global Corticosteroid Injections for Joint Pain Market?

The Triamcinolone-based injections segment held the largest market share in 2023.

5) Who are the key market players in the Global Corticosteroid Injections for Joint Pain Market?

Key players include Pfizer Inc., Mylan N.V., Sanofi S.A., Johnson & Johnson, Teva Pharmaceuticals, and AbbVie Inc.